Global Paroxysmal Nocturnal Hemoglobinuria Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Paroxysmal Nocturnal Hemoglobinuria Drug market size was valued at USD 3292.6 million in 2022 and is forecast to a readjusted size of USD 7482 million by 2029 with a CAGR of 12.4% during review period.
The Global Info Research report includes an overview of the development of the Paroxysmal Nocturnal Hemoglobinuria Drug industry chain, the market status of Clinic (Eculizumab, Ravulizumab), Hospital (Eculizumab, Ravulizumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Paroxysmal Nocturnal Hemoglobinuria Drug.
Regionally, the report analyzes the Paroxysmal Nocturnal Hemoglobinuria Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Paroxysmal Nocturnal Hemoglobinuria Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Paroxysmal Nocturnal Hemoglobinuria Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Paroxysmal Nocturnal Hemoglobinuria Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Eculizumab, Ravulizumab).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Regional Analysis: The report involves examining the Paroxysmal Nocturnal Hemoglobinuria Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Paroxysmal Nocturnal Hemoglobinuria Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Paroxysmal Nocturnal Hemoglobinuria Drug:
Company Analysis: Report covers individual Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Paroxysmal Nocturnal Hemoglobinuria Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Clinic, Hospital).
Technology Analysis: Report covers specific technologies relevant to Paroxysmal Nocturnal Hemoglobinuria Drug. It assesses the current state, advancements, and potential future developments in Paroxysmal Nocturnal Hemoglobinuria Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Paroxysmal Nocturnal Hemoglobinuria Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Paroxysmal Nocturnal Hemoglobinuria Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Paroxysmal Nocturnal Hemoglobinuria Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, with price, sales, revenue and global market share of Paroxysmal Nocturnal Hemoglobinuria Drug from 2018 to 2023.
Chapter 3, the Paroxysmal Nocturnal Hemoglobinuria Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Paroxysmal Nocturnal Hemoglobinuria Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Paroxysmal Nocturnal Hemoglobinuria Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Paroxysmal Nocturnal Hemoglobinuria Drug.
Chapter 14 and 15, to describe Paroxysmal Nocturnal Hemoglobinuria Drug sales channel, distributors, customers, research findings and conclusion.
The Global Info Research report includes an overview of the development of the Paroxysmal Nocturnal Hemoglobinuria Drug industry chain, the market status of Clinic (Eculizumab, Ravulizumab), Hospital (Eculizumab, Ravulizumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Paroxysmal Nocturnal Hemoglobinuria Drug.
Regionally, the report analyzes the Paroxysmal Nocturnal Hemoglobinuria Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Paroxysmal Nocturnal Hemoglobinuria Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Paroxysmal Nocturnal Hemoglobinuria Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Paroxysmal Nocturnal Hemoglobinuria Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Eculizumab, Ravulizumab).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Regional Analysis: The report involves examining the Paroxysmal Nocturnal Hemoglobinuria Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Paroxysmal Nocturnal Hemoglobinuria Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Paroxysmal Nocturnal Hemoglobinuria Drug:
Company Analysis: Report covers individual Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Paroxysmal Nocturnal Hemoglobinuria Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Clinic, Hospital).
Technology Analysis: Report covers specific technologies relevant to Paroxysmal Nocturnal Hemoglobinuria Drug. It assesses the current state, advancements, and potential future developments in Paroxysmal Nocturnal Hemoglobinuria Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Paroxysmal Nocturnal Hemoglobinuria Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Paroxysmal Nocturnal Hemoglobinuria Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Eculizumab
- Ravulizumab
- Others
- Clinic
- Hospital
- Others
- Apellis Pharmaceuticals
- Alexion Pharmaceuticals Inc
- Akari Therapeutics Plc
- CinnaGen Co
- Ra Pharmaceuticals Inc
- Amgen Inc
- Achillion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Regeneron Pharmaceuticals Inc
- BIOCAD
- Samsung Bioepis
- Amyndas Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- LGM Pharma.
- Lannett
- NorthStar Rx LLC
- Abbott
- Par Pharmaceutical
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Paroxysmal Nocturnal Hemoglobinuria Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, with price, sales, revenue and global market share of Paroxysmal Nocturnal Hemoglobinuria Drug from 2018 to 2023.
Chapter 3, the Paroxysmal Nocturnal Hemoglobinuria Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Paroxysmal Nocturnal Hemoglobinuria Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Paroxysmal Nocturnal Hemoglobinuria Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Paroxysmal Nocturnal Hemoglobinuria Drug.
Chapter 14 and 15, to describe Paroxysmal Nocturnal Hemoglobinuria Drug sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Paroxysmal Nocturnal Hemoglobinuria Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Eculizumab
1.3.3 Ravulizumab
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinic
1.4.3 Hospital
1.4.4 Others
1.5 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size & Forecast
1.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (2018-2029)
1.5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Apellis Pharmaceuticals
2.1.1 Apellis Pharmaceuticals Details
2.1.2 Apellis Pharmaceuticals Major Business
2.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.1.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Apellis Pharmaceuticals Recent Developments/Updates
2.2 Alexion Pharmaceuticals Inc
2.2.1 Alexion Pharmaceuticals Inc Details
2.2.2 Alexion Pharmaceuticals Inc Major Business
2.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.2.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Alexion Pharmaceuticals Inc Recent Developments/Updates
2.3 Akari Therapeutics Plc
2.3.1 Akari Therapeutics Plc Details
2.3.2 Akari Therapeutics Plc Major Business
2.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Akari Therapeutics Plc Recent Developments/Updates
2.4 CinnaGen Co
2.4.1 CinnaGen Co Details
2.4.2 CinnaGen Co Major Business
2.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.4.4 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 CinnaGen Co Recent Developments/Updates
2.5 Ra Pharmaceuticals Inc
2.5.1 Ra Pharmaceuticals Inc Details
2.5.2 Ra Pharmaceuticals Inc Major Business
2.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.5.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Ra Pharmaceuticals Inc Recent Developments/Updates
2.6 Amgen Inc
2.6.1 Amgen Inc Details
2.6.2 Amgen Inc Major Business
2.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.6.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Amgen Inc Recent Developments/Updates
2.7 Achillion Pharmaceuticals Inc
2.7.1 Achillion Pharmaceuticals Inc Details
2.7.2 Achillion Pharmaceuticals Inc Major Business
2.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.7.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Achillion Pharmaceuticals Inc Recent Developments/Updates
2.8 Alnylam Pharmaceuticals Inc
2.8.1 Alnylam Pharmaceuticals Inc Details
2.8.2 Alnylam Pharmaceuticals Inc Major Business
2.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.8.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Alnylam Pharmaceuticals Inc Recent Developments/Updates
2.9 F. Hoffmann-La Roche Ltd
2.9.1 F. Hoffmann-La Roche Ltd Details
2.9.2 F. Hoffmann-La Roche Ltd Major Business
2.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.9.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.10 Novartis AG
2.10.1 Novartis AG Details
2.10.2 Novartis AG Major Business
2.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.10.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Novartis AG Recent Developments/Updates
2.11 Regeneron Pharmaceuticals Inc
2.11.1 Regeneron Pharmaceuticals Inc Details
2.11.2 Regeneron Pharmaceuticals Inc Major Business
2.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.11.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
2.12 BIOCAD
2.12.1 BIOCAD Details
2.12.2 BIOCAD Major Business
2.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.12.4 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 BIOCAD Recent Developments/Updates
2.13 Samsung Bioepis
2.13.1 Samsung Bioepis Details
2.13.2 Samsung Bioepis Major Business
2.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.13.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Samsung Bioepis Recent Developments/Updates
2.14 Amyndas Pharmaceuticals
2.14.1 Amyndas Pharmaceuticals Details
2.14.2 Amyndas Pharmaceuticals Major Business
2.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.14.4 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Amyndas Pharmaceuticals Recent Developments/Updates
2.15 Teva Pharmaceutical Industries Ltd.
2.15.1 Teva Pharmaceutical Industries Ltd. Details
2.15.2 Teva Pharmaceutical Industries Ltd. Major Business
2.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.15.4 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
2.16 LGM Pharma.
2.16.1 LGM Pharma. Details
2.16.2 LGM Pharma. Major Business
2.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.16.4 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 LGM Pharma. Recent Developments/Updates
2.17 Lannett
2.17.1 Lannett Details
2.17.2 Lannett Major Business
2.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.17.4 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Lannett Recent Developments/Updates
2.18 NorthStar Rx LLC
2.18.1 NorthStar Rx LLC Details
2.18.2 NorthStar Rx LLC Major Business
2.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.18.4 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 NorthStar Rx LLC Recent Developments/Updates
2.19 Abbott
2.19.1 Abbott Details
2.19.2 Abbott Major Business
2.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.19.4 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Abbott Recent Developments/Updates
2.20 Par Pharmaceutical
2.20.1 Par Pharmaceutical Details
2.20.2 Par Pharmaceutical Major Business
2.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.20.4 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Par Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY MANUFACTURER
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Manufacturer (2018-2023)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Paroxysmal Nocturnal Hemoglobinuria Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer Market Share in 2022
3.5 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Overall Company Footprint Analysis
3.5.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Region Footprint
3.5.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Type Footprint
3.5.3 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2029)
4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Region (2018-2029)
4.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.5 South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type (2018-2029)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
6.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application (2018-2029)
6.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
7.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
7.3 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
7.3.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
8.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
8.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
8.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region
9.3.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
10.2 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
10.3 South America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
10.3.1 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
11.3.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
12.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
12.3 Paroxysmal Nocturnal Hemoglobinuria Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Paroxysmal Nocturnal Hemoglobinuria Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Paroxysmal Nocturnal Hemoglobinuria Drug
13.3 Paroxysmal Nocturnal Hemoglobinuria Drug Production Process
13.4 Paroxysmal Nocturnal Hemoglobinuria Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Paroxysmal Nocturnal Hemoglobinuria Drug Typical Distributors
14.3 Paroxysmal Nocturnal Hemoglobinuria Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Paroxysmal Nocturnal Hemoglobinuria Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Eculizumab
1.3.3 Ravulizumab
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinic
1.4.3 Hospital
1.4.4 Others
1.5 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size & Forecast
1.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (2018-2029)
1.5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Apellis Pharmaceuticals
2.1.1 Apellis Pharmaceuticals Details
2.1.2 Apellis Pharmaceuticals Major Business
2.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.1.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Apellis Pharmaceuticals Recent Developments/Updates
2.2 Alexion Pharmaceuticals Inc
2.2.1 Alexion Pharmaceuticals Inc Details
2.2.2 Alexion Pharmaceuticals Inc Major Business
2.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.2.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Alexion Pharmaceuticals Inc Recent Developments/Updates
2.3 Akari Therapeutics Plc
2.3.1 Akari Therapeutics Plc Details
2.3.2 Akari Therapeutics Plc Major Business
2.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Akari Therapeutics Plc Recent Developments/Updates
2.4 CinnaGen Co
2.4.1 CinnaGen Co Details
2.4.2 CinnaGen Co Major Business
2.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.4.4 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 CinnaGen Co Recent Developments/Updates
2.5 Ra Pharmaceuticals Inc
2.5.1 Ra Pharmaceuticals Inc Details
2.5.2 Ra Pharmaceuticals Inc Major Business
2.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.5.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Ra Pharmaceuticals Inc Recent Developments/Updates
2.6 Amgen Inc
2.6.1 Amgen Inc Details
2.6.2 Amgen Inc Major Business
2.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.6.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Amgen Inc Recent Developments/Updates
2.7 Achillion Pharmaceuticals Inc
2.7.1 Achillion Pharmaceuticals Inc Details
2.7.2 Achillion Pharmaceuticals Inc Major Business
2.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.7.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Achillion Pharmaceuticals Inc Recent Developments/Updates
2.8 Alnylam Pharmaceuticals Inc
2.8.1 Alnylam Pharmaceuticals Inc Details
2.8.2 Alnylam Pharmaceuticals Inc Major Business
2.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.8.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Alnylam Pharmaceuticals Inc Recent Developments/Updates
2.9 F. Hoffmann-La Roche Ltd
2.9.1 F. Hoffmann-La Roche Ltd Details
2.9.2 F. Hoffmann-La Roche Ltd Major Business
2.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.9.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.10 Novartis AG
2.10.1 Novartis AG Details
2.10.2 Novartis AG Major Business
2.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.10.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Novartis AG Recent Developments/Updates
2.11 Regeneron Pharmaceuticals Inc
2.11.1 Regeneron Pharmaceuticals Inc Details
2.11.2 Regeneron Pharmaceuticals Inc Major Business
2.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.11.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
2.12 BIOCAD
2.12.1 BIOCAD Details
2.12.2 BIOCAD Major Business
2.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.12.4 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 BIOCAD Recent Developments/Updates
2.13 Samsung Bioepis
2.13.1 Samsung Bioepis Details
2.13.2 Samsung Bioepis Major Business
2.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.13.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Samsung Bioepis Recent Developments/Updates
2.14 Amyndas Pharmaceuticals
2.14.1 Amyndas Pharmaceuticals Details
2.14.2 Amyndas Pharmaceuticals Major Business
2.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.14.4 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Amyndas Pharmaceuticals Recent Developments/Updates
2.15 Teva Pharmaceutical Industries Ltd.
2.15.1 Teva Pharmaceutical Industries Ltd. Details
2.15.2 Teva Pharmaceutical Industries Ltd. Major Business
2.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.15.4 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
2.16 LGM Pharma.
2.16.1 LGM Pharma. Details
2.16.2 LGM Pharma. Major Business
2.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.16.4 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 LGM Pharma. Recent Developments/Updates
2.17 Lannett
2.17.1 Lannett Details
2.17.2 Lannett Major Business
2.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.17.4 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Lannett Recent Developments/Updates
2.18 NorthStar Rx LLC
2.18.1 NorthStar Rx LLC Details
2.18.2 NorthStar Rx LLC Major Business
2.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.18.4 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 NorthStar Rx LLC Recent Developments/Updates
2.19 Abbott
2.19.1 Abbott Details
2.19.2 Abbott Major Business
2.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.19.4 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Abbott Recent Developments/Updates
2.20 Par Pharmaceutical
2.20.1 Par Pharmaceutical Details
2.20.2 Par Pharmaceutical Major Business
2.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
2.20.4 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Par Pharmaceutical Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY MANUFACTURER
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Manufacturer (2018-2023)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Paroxysmal Nocturnal Hemoglobinuria Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer Market Share in 2022
3.5 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Overall Company Footprint Analysis
3.5.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Region Footprint
3.5.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Type Footprint
3.5.3 Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2029)
4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Region (2018-2029)
4.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.5 South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type (2018-2029)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
6.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application (2018-2029)
6.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
7.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
7.3 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
7.3.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
8.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
8.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
8.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region
9.3.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
10.2 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
10.3 South America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
10.3.1 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country
11.3.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
12.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
12.3 Paroxysmal Nocturnal Hemoglobinuria Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Paroxysmal Nocturnal Hemoglobinuria Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Paroxysmal Nocturnal Hemoglobinuria Drug
13.3 Paroxysmal Nocturnal Hemoglobinuria Drug Production Process
13.4 Paroxysmal Nocturnal Hemoglobinuria Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Paroxysmal Nocturnal Hemoglobinuria Drug Typical Distributors
14.3 Paroxysmal Nocturnal Hemoglobinuria Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Apellis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Apellis Pharmaceuticals Major Business
Table 5. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 6. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Apellis Pharmaceuticals Recent Developments/Updates
Table 8. Alexion Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 9. Alexion Pharmaceuticals Inc Major Business
Table 10. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 11. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Alexion Pharmaceuticals Inc Recent Developments/Updates
Table 13. Akari Therapeutics Plc Basic Information, Manufacturing Base and Competitors
Table 14. Akari Therapeutics Plc Major Business
Table 15. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 16. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Akari Therapeutics Plc Recent Developments/Updates
Table 18. CinnaGen Co Basic Information, Manufacturing Base and Competitors
Table 19. CinnaGen Co Major Business
Table 20. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 21. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. CinnaGen Co Recent Developments/Updates
Table 23. Ra Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 24. Ra Pharmaceuticals Inc Major Business
Table 25. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 26. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Ra Pharmaceuticals Inc Recent Developments/Updates
Table 28. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 29. Amgen Inc Major Business
Table 30. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 31. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Amgen Inc Recent Developments/Updates
Table 33. Achillion Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 34. Achillion Pharmaceuticals Inc Major Business
Table 35. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 36. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Achillion Pharmaceuticals Inc Recent Developments/Updates
Table 38. Alnylam Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 39. Alnylam Pharmaceuticals Inc Major Business
Table 40. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 41. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Alnylam Pharmaceuticals Inc Recent Developments/Updates
Table 43. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 44. F. Hoffmann-La Roche Ltd Major Business
Table 45. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 46. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 48. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 49. Novartis AG Major Business
Table 50. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 51. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Novartis AG Recent Developments/Updates
Table 53. Regeneron Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 54. Regeneron Pharmaceuticals Inc Major Business
Table 55. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 56. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Regeneron Pharmaceuticals Inc Recent Developments/Updates
Table 58. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 59. BIOCAD Major Business
Table 60. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 61. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. BIOCAD Recent Developments/Updates
Table 63. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 64. Samsung Bioepis Major Business
Table 65. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 66. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Samsung Bioepis Recent Developments/Updates
Table 68. Amyndas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 69. Amyndas Pharmaceuticals Major Business
Table 70. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 71. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Amyndas Pharmaceuticals Recent Developments/Updates
Table 73. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 74. Teva Pharmaceutical Industries Ltd. Major Business
Table 75. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 76. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 78. LGM Pharma. Basic Information, Manufacturing Base and Competitors
Table 79. LGM Pharma. Major Business
Table 80. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 81. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. LGM Pharma. Recent Developments/Updates
Table 83. Lannett Basic Information, Manufacturing Base and Competitors
Table 84. Lannett Major Business
Table 85. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 86. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Lannett Recent Developments/Updates
Table 88. NorthStar Rx LLC Basic Information, Manufacturing Base and Competitors
Table 89. NorthStar Rx LLC Major Business
Table 90. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 91. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. NorthStar Rx LLC Recent Developments/Updates
Table 93. Abbott Basic Information, Manufacturing Base and Competitors
Table 94. Abbott Major Business
Table 95. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 96. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. Abbott Recent Developments/Updates
Table 98. Par Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 99. Par Pharmaceutical Major Business
Table 100. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 101. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. Par Pharmaceutical Recent Developments/Updates
Table 103. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 104. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 105. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 106. Market Position of Manufacturers in Paroxysmal Nocturnal Hemoglobinuria Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 107. Head Office and Paroxysmal Nocturnal Hemoglobinuria Drug Production Site of Key Manufacturer
Table 108. Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Type Footprint
Table 109. Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Application Footprint
Table 110. Paroxysmal Nocturnal Hemoglobinuria Drug New Market Entrants and Barriers to Market Entry
Table 111. Paroxysmal Nocturnal Hemoglobinuria Drug Mergers, Acquisition, Agreements, and Collaborations
Table 112. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 113. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 114. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 115. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 116. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 117. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 118. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 119. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 120. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 121. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 122. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 123. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 124. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 127. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 128. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 129. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 130. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 131. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 132. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 133. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 134. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 135. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 136. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 137. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 138. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 139. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 140. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 141. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 142. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 143. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 144. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 145. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 146. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 147. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 148. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 149. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 150. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 151. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 152. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 153. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 154. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 155. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 156. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 157. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 158. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 159. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 160. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 161. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 162. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 163. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 164. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 165. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 166. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 167. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 168. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 169. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 170. Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material
Table 171. Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug Raw Materials
Table 172. Paroxysmal Nocturnal Hemoglobinuria Drug Typical Distributors
Table 173. Paroxysmal Nocturnal Hemoglobinuria Drug Typical Customers
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Apellis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Apellis Pharmaceuticals Major Business
Table 5. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 6. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Apellis Pharmaceuticals Recent Developments/Updates
Table 8. Alexion Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 9. Alexion Pharmaceuticals Inc Major Business
Table 10. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 11. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Alexion Pharmaceuticals Inc Recent Developments/Updates
Table 13. Akari Therapeutics Plc Basic Information, Manufacturing Base and Competitors
Table 14. Akari Therapeutics Plc Major Business
Table 15. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 16. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Akari Therapeutics Plc Recent Developments/Updates
Table 18. CinnaGen Co Basic Information, Manufacturing Base and Competitors
Table 19. CinnaGen Co Major Business
Table 20. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 21. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. CinnaGen Co Recent Developments/Updates
Table 23. Ra Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 24. Ra Pharmaceuticals Inc Major Business
Table 25. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 26. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Ra Pharmaceuticals Inc Recent Developments/Updates
Table 28. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 29. Amgen Inc Major Business
Table 30. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 31. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Amgen Inc Recent Developments/Updates
Table 33. Achillion Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 34. Achillion Pharmaceuticals Inc Major Business
Table 35. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 36. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Achillion Pharmaceuticals Inc Recent Developments/Updates
Table 38. Alnylam Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 39. Alnylam Pharmaceuticals Inc Major Business
Table 40. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 41. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Alnylam Pharmaceuticals Inc Recent Developments/Updates
Table 43. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 44. F. Hoffmann-La Roche Ltd Major Business
Table 45. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 46. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 48. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 49. Novartis AG Major Business
Table 50. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 51. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Novartis AG Recent Developments/Updates
Table 53. Regeneron Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 54. Regeneron Pharmaceuticals Inc Major Business
Table 55. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 56. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Regeneron Pharmaceuticals Inc Recent Developments/Updates
Table 58. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 59. BIOCAD Major Business
Table 60. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 61. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. BIOCAD Recent Developments/Updates
Table 63. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 64. Samsung Bioepis Major Business
Table 65. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 66. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Samsung Bioepis Recent Developments/Updates
Table 68. Amyndas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 69. Amyndas Pharmaceuticals Major Business
Table 70. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 71. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Amyndas Pharmaceuticals Recent Developments/Updates
Table 73. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 74. Teva Pharmaceutical Industries Ltd. Major Business
Table 75. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 76. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 78. LGM Pharma. Basic Information, Manufacturing Base and Competitors
Table 79. LGM Pharma. Major Business
Table 80. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 81. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. LGM Pharma. Recent Developments/Updates
Table 83. Lannett Basic Information, Manufacturing Base and Competitors
Table 84. Lannett Major Business
Table 85. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 86. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Lannett Recent Developments/Updates
Table 88. NorthStar Rx LLC Basic Information, Manufacturing Base and Competitors
Table 89. NorthStar Rx LLC Major Business
Table 90. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 91. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. NorthStar Rx LLC Recent Developments/Updates
Table 93. Abbott Basic Information, Manufacturing Base and Competitors
Table 94. Abbott Major Business
Table 95. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 96. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. Abbott Recent Developments/Updates
Table 98. Par Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 99. Par Pharmaceutical Major Business
Table 100. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product and Services
Table 101. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. Par Pharmaceutical Recent Developments/Updates
Table 103. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 104. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 105. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 106. Market Position of Manufacturers in Paroxysmal Nocturnal Hemoglobinuria Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 107. Head Office and Paroxysmal Nocturnal Hemoglobinuria Drug Production Site of Key Manufacturer
Table 108. Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Type Footprint
Table 109. Paroxysmal Nocturnal Hemoglobinuria Drug Market: Company Product Application Footprint
Table 110. Paroxysmal Nocturnal Hemoglobinuria Drug New Market Entrants and Barriers to Market Entry
Table 111. Paroxysmal Nocturnal Hemoglobinuria Drug Mergers, Acquisition, Agreements, and Collaborations
Table 112. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 113. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 114. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 115. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 116. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 117. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 118. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 119. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 120. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 121. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 122. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 123. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 124. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 127. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 128. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 129. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 130. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 131. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 132. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 133. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 134. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 135. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 136. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 137. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 138. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 139. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 140. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 141. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 142. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 143. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 144. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 145. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 146. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 147. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 148. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 149. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 150. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 151. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 152. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 153. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 154. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 155. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 156. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 157. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 158. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 159. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 160. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 161. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 162. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 163. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 164. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 165. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 166. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 167. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 168. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 169. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 170. Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material
Table 171. Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug Raw Materials
Table 172. Paroxysmal Nocturnal Hemoglobinuria Drug Typical Distributors
Table 173. Paroxysmal Nocturnal Hemoglobinuria Drug Typical Customers
LIST OF FIGURES
s
Figure 1. Paroxysmal Nocturnal Hemoglobinuria Drug Picture
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Type in 2022
Figure 4. Eculizumab Examples
Figure 5. Ravulizumab Examples
Figure 6. Others Examples
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Application in 2022
Figure 9. Clinic Examples
Figure 10. Hospital Examples
Figure 11. Others Examples
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Paroxysmal Nocturnal Hemoglobinuria Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Region (2018-2029)
Figure 54. China Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
Figure 75. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
Figure 76. Paroxysmal Nocturnal Hemoglobinuria Drug Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug in 2022
Figure 79. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 80. Paroxysmal Nocturnal Hemoglobinuria Drug Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
s
Figure 1. Paroxysmal Nocturnal Hemoglobinuria Drug Picture
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Type in 2022
Figure 4. Eculizumab Examples
Figure 5. Ravulizumab Examples
Figure 6. Others Examples
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Application in 2022
Figure 9. Clinic Examples
Figure 10. Hospital Examples
Figure 11. Others Examples
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Paroxysmal Nocturnal Hemoglobinuria Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Region (2018-2029)
Figure 54. China Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Paroxysmal Nocturnal Hemoglobinuria Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
Figure 75. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
Figure 76. Paroxysmal Nocturnal Hemoglobinuria Drug Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug in 2022
Figure 79. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 80. Paroxysmal Nocturnal Hemoglobinuria Drug Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
